Nanobiotix (NASDAQ:NBTX) Shares Gap Up - Still a Buy?

Key Points

• Nanobiotix's share price gapped up from $14.75 to $15.44 at market opening, closing at $15.50 with significant trading volume.
• Analysts maintain a consensus rating of "Moderate Buy" on Nanobiotix, with target prices ranging from $11.00 to $14.00.
• Institutions hold 38.81% of Nanobiotix stocks, with Jane Street Group LLC recently acquiring 23,283 shares valued at approximately $73,000.

Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Get Free Report)'s share price gapped up before the market opened on Friday . The stock had previously closed at $14.75, but opened at $15.44. Nanobiotix shares last traded at $15.50, with a volume of 10,049 shares trading hands.

Analysts Set New Price Targets

A number of equities analysts recently commented on NBTX shares. HC Wainwright restated a "buy" rating on shares of Nanobiotix in a report on Friday, September 19th. Leerink Partners set a $14.00 target price on Nanobiotix in a report on Thursday, September 18th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Nanobiotix presently has a consensus rating of "Moderate Buy" and a consensus target price of $11.00.

Nanobiotix Stock Up 6.4%

The business has a fifty day simple moving average of $8.72 and a 200-day simple moving average of $5.61.

Hedge Funds Weigh In On Nanobiotix

An institutional investor recently bought a new position in Nanobiotix stock. Jane Street Group LLC purchased a new stake in shares of Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 23,283 shares of the company's stock, valued at approximately $73,000. Institutional investors and hedge funds own 38.81% of the company's stock.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.